Interferon therapy for orbital infiltration secondary to Erdheim-Chester disease - 03/09/11
Doi : 10.1016/S0002-9394(01)01141-2
Bita Esmaeli, MD ⁎, a 
, Amir Ahmadi, MD a, Rosa Tang, MD a, Jade Schiffman, MD a, Razelle Kurzrock, MD b
, Amir Ahmadi, MD a, Rosa Tang, MD a, Jade Schiffman, MD a, Razelle Kurzrock, MD b a Ophthalmology Section, Department of Plastic Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA (B.E., A.A., R.T., J.S.)
b Department of Bioimmunotherapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA (R.K.)
*Inquiries to Bita Esmaeli, MD, Ophthalmology Section, Department of Plastic Surgery, Box 443, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX USA 77030; fax: (713) 794-5492
Abstract |
PURPOSE: To describe a 55-year-old male with Erdheim-Chester disease with bilateral orbital infiltration and visual loss who was successfully treated with interferon-alpha.
METHODS: Interventional case report.
RESULTS: The patient was treated with interferon-alpha and had an improvement in his clinical signs, including his visual acuity, after 4 weeks of interferon therapy.
CONCLUSION: Interferon-alpha can be effective in the treatment of orbital infiltration secondary to Erdheim-Chester disease.
Le texte complet de cet article est disponible en PDF.© 2001
Elsevier Science Inc. Tous droits réservés.
Vol 132 - N° 6
P. 945-947 - décembre 2001 Retour au numéro
Article précédent
- Metastatic adenocarcinoma with rupture through the bruch membrane simulating a choroidal melanoma
- Russell W. Read, Ronald L. Green, Narsing A. Rao
- Cataract and phthisis bulbi after laser photoablation for threshold retinopathy of prematurity
- Philip J. Ferrone, Michael J. Banach, Michael T. Trese
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?